I'm LongbridgeAI, I can summarize articles.Cantor Fitzgerald analyst Carter Gould maintained a Hold rating on Bristol-Myers Squibb (BMY) with a $53.00 price target. This follows mixed sentiment from other firms: Leerink Partners also issued a Hold, while Morgan Stanley assigned a Sell rating to the stock on the same day.
In a report released today, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Bristol-Myers Squibb, with a price target of $53.00.
Gould covers the Healthcare sector, focusing on stocks such as Amgen, Bristol-Myers Squibb, and Eli Lilly & Co. According to TipRanks, Gould has an average return of 6.4% and a 53.19% success rate on recommended stocks.
In addition to Cantor Fitzgerald, Bristol-Myers Squibb also received a Hold from Leerink Partners’s David Risinger in a report issued yesterday. However, on the same day, Morgan Stanley assigned a Sell rating to Bristol-Myers Squibb (NYSE: BMY).